Understanding DNA Repair Pathways

DNA repair pathways are fundamental cellular mechanisms that safeguard the integrity of the genome. Every day, human cells face thousands of DNA lesions from endogenous sources such as reactive oxygen species, replication errors, and metabolic byproducts, as well as from exogenous agents like ultraviolet radiation, chemicals, and certain chemotherapeutic drugs. Without efficient repair systems, these lesions would lead to mutations, chromosomal aberrations, and ultimately genomic instability — a hallmark of cancer. The study of these pathways has not only illuminated the basic biology of cancer but has also opened the door to targeted therapies that exploit repair deficiencies in tumor cells.

Cells have evolved several distinct but interconnected DNA repair pathways, each specialized for a particular type of damage. The major pathways include base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination (HR), and non-homologous end joining (NHEJ). Understanding how these pathways function and how they fail in cancer is critical for developing effective treatments.

Key DNA Repair Pathways in Detail

Base Excision Repair (BER)

Base excision repair corrects small, non-bulky DNA lesions such as oxidized bases, alkylated bases, and abasic sites. It is initiated by a DNA glycosylase that recognizes and removes the damaged base, creating an abasic site. An endonuclease then cleaves the DNA backbone, and the resulting gap is filled by a DNA polymerase and sealed by a DNA ligase. BER is essential for repairing damage from endogenous cellular processes and is often impaired in certain cancers. For example, mutations in the OGG1 gene, which encodes a glycosylase that repairs 8-oxoguanine, have been linked to increased lung cancer risk.

Nucleotide Excision Repair (NER)

Nucleotide excision repair handles bulky DNA adducts, such as those caused by ultraviolet light (pyrimidine dimers) and certain chemotherapeutic agents like cisplatin. NER excises a short oligonucleotide containing the damaged lesion, and the resulting gap is filled by DNA synthesis and ligation. There are two subpathways: global genome NER (GG-NER) and transcription-coupled NER (TC-NER). Defects in NER are associated with xeroderma pigmentosum, a condition with a dramatically elevated risk of skin cancer due to inability to repair UV-induced damage. Cancers such as melanoma and certain lung cancers may also harbor NER deficiencies, providing a potential therapeutic vulnerability.

Mismatch Repair (MMR)

Mismatch repair corrects errors that escape proofreading during DNA replication, such as base-base mismatches and insertion-deletion loops. MMR proteins (e.g., MSH2, MSH6, MLH1, PMS2) recognize the mismatch, excise the newly synthesized strand, and resynthesize the correct sequence. Deficiencies in MMR lead to a mutator phenotype characterized by microsatellite instability (MSI). About 15% of colorectal cancers and a subset of endometrial, gastric, and other cancers are MMR-deficient. These tumors are highly immunogenic and respond well to immune checkpoint inhibitors, such as pembrolizumab, which was approved for MSI-high cancers regardless of tissue origin.

Homologous Recombination (HR)

Homologous recombination is a high-fidelity mechanism for repairing double-strand breaks (DSBs) and interstrand crosslinks. It uses a sister chromatid as a template, ensuring accurate repair. Key proteins include BRCA1, BRCA2, ATM, ATR, and RAD51. Mutations in BRCA1 or BRCA2 are well-known risk factors for breast, ovarian, pancreatic, and prostate cancers. HR-deficient tumors are unable to repair DSBs accurately and thus rely on alternative pathways. This vulnerability is the basis for the use of PARP inhibitors, which exploit synthetic lethality (discussed below).

Non-Homologous End Joining (NHEJ)

Non-homologous end joining is a faster but error-prone pathway for repairing DSBs. It directly ligates broken DNA ends without requiring a homologous template, often resulting in small insertions or deletions. NHEJ operates throughout the cell cycle, while HR is active mainly in S and G2 phases. Key proteins include Ku70/Ku80, DNA-PKcs, XRCC4, and Ligase IV. NHEJ is critical for V(D)J recombination in the immune system but can also promote genomic instability if misregulated. In cancer, NHEJ can be targeted to sensitize cells to radiation or DSB-inducing drugs.

Synthetic Lethality as a Therapeutic Strategy

The concept of synthetic lethality is central to targeting DNA repair pathways in cancer. Two genes are synthetically lethal if a defect in either alone is viable, but simultaneous defects in both cause cell death. In cancer therapy, the tumor already harbors a deficiency in one DNA repair pathway; the therapeutic agent then inhibits a compensatory pathway, selectively killing cancer cells while sparing normal cells with intact repair.

The most prominent example involves PARP (poly ADP-ribose polymerase) and BRCA mutations. PARP1 is a key enzyme in base excision repair and also plays a role in the repair of single-strand breaks. In cells with defective HR due to BRCA1/2 mutations, PARP inhibition leads to persistent single-strand breaks that collapse replication forks into double-strand breaks. Because HR cannot repair these breaks, genomic instability accumulates, triggering cell death. This strategy has revolutionized the treatment of BRCA-mutated ovarian and breast cancers.

Clinical Applications and Approved Drugs

PARP inhibitors (PARPis) are the most successful class of drugs targeting DNA repair. Currently approved PARPis include olaparib, niraparib, rucaparib, talazoparib, and veliparib. They are used in ovarian, breast, pancreatic, and prostate cancers with BRCA1/2 mutations or other HR deficiency markers. For instance, olaparib was first approved in 2014 for germline BRCA-mutated advanced ovarian cancer after three or more lines of chemotherapy, and later expanded to include maintenance therapy and treatment of HR-deficient tumors.

Other DNA repair-targeted therapies are emerging. For example, the ATR inhibitor berzosertib is being evaluated in clinical trials for tumors with ATM loss or other replication stress markers. The DNA-PK inhibitor M3814 (peposertib) is being tested as a radiosensitizer. Additionally, immune checkpoint inhibitors like pembrolizumab have been approved for MMR-deficient (MSI-high) solid tumors, leveraging the high mutation burden to stimulate antitumor immunity.

For more information on approved PARP inhibitors and their indications, consult the FDA label for olaparib and the NCCN guidelines for genetic/familial high-risk assessment.

Challenges: Resistance to DNA Repair–Targeted Therapies

Despite their initial efficacy, tumors frequently develop resistance to DNA repair inhibitors. Resistance mechanisms to PARP inhibitors include:

  • Restoration of HR: Secondary mutations in BRCA1/2 that restore the open reading frame and allow functional protein expression, re-establishing HR activity.
  • Drug efflux: Upregulation of ATP-binding cassette transporters such as P-glycoprotein, which reduces intracellular drug concentration.
  • PARP1 mutation or loss: Mutations in PARP1 that reduce drug binding or loss of PARP1 expression, eliminating the target.
  • Alternative repair pathway activation: Upregulation of NHEJ or other end-joining pathways that compensate for HR deficiency.

Understanding these resistance mechanisms is crucial for developing next-generation therapies. Strategies to overcome resistance include using PARP inhibitors that are less susceptible to efflux (e.g., talazoparib is a poor substrate for P-glycoprotein), combining PARPis with ATR or ATM inhibitors to block compensatory pathways, or using proteolysis-targeting chimeras (PROTACs) to degrade PARP1.

For a detailed review of resistance mechanisms, see this article in Nature Reviews Cancer.

Emerging Targets and Future Directions

Beyond PARP, several other DNA repair proteins are being explored as therapeutic targets. ATR kinase is a key sensor of replication stress and is essential in HR-deficient cells. Inhibitors of ATR (e.g., berzosertib, ceralasertib) are in phase I/II trials for various solid tumors, often combined with PARP inhibitors or chemotherapy. Similarly, inhibitors of ATM, DNA-PK, WEE1, and CHK1 are under investigation.

Another exciting area is the use of DNA repair inhibitors to enhance the efficacy of radiotherapy. NHEJ inhibitors (e.g., DNA-PK inhibitors) can sensitize tumors to ionizing radiation, while sparing normal tissues if the tumor is deficient in HR. Preclinical studies suggest that combining radiation with PARP inhibitors or ATM inhibitors could improve local control in glioblastoma and pancreatic cancer.

Biomarker development is critical for patient selection. Homologous recombination deficiency (HRD) scores, based on genomic scars such as large-scale state transitions and loss of heterozygosity, are used to identify tumors likely to respond to PARP inhibitors. However, these tests are imperfect, and research continues to identify more robust predictive markers, such as PALB2 mutations, RAD51C/D promoter methylation, or functional assays of RAD51 foci formation.

Finally, the interplay between DNA repair and the immune system offers new combinatorial strategies. MMR-deficient tumors are highly responsive to checkpoint inhibitors due to high mutational burden, but PARP inhibitors can also upregulate PD-L1 expression and increase tumor immunogenicity. Combining PARPis with anti-PD-1/PD-L1 antibodies is being tested in multiple trials, with early data showing promising response rates in BRCA-mutated ovarian cancer.

For the latest clinical trial landscape, refer to ClinicalTrials.gov search results for DNA repair inhibitors.

Conclusion

Targeting DNA repair pathways has become a cornerstone of precision oncology. From the success of PARP inhibitors in BRCA-mutated cancers to immunotherapy for MMR-deficient tumors, the exploitation of synthetic lethality and repair deficiencies continues to expand the therapeutic arsenal. Overcoming resistance, identifying predictive biomarkers, and combining repair inhibitors with other modalities — including radiation and immunotherapy — represent the next frontiers. As our understanding of DNA repair deepens, new targets will emerge, offering hope for more effective and personalized cancer treatments that improve outcomes for patients with a wide range of malignancies.